Want to see HK:1952 full AI Analyst Report?
Everest Medicines Ltd. (1952) AI Stock Analysis
Top Page
Everest Medicines Ltd.
(HKEX:1952)
The score is driven primarily by mixed financial performance: rapid revenue growth and solid gross margins are offset by ongoing net losses and continued cash burn. Technicals add support as the stock is in an uptrend with positive momentum. Valuation remains a headwind due to negative earnings and no stated dividend yield.
Everest Medicines Ltd. (1952) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 9.55B
- Dividend Yield
- ―
- Average Volume (3M)
- 9.41M
- Price to Earnings (P/E)
- -145.1
- Beta (1Y)
- 1.02
- Revenue Growth
- 192.64%
- EPS Growth
- 92.31%
- Country
- Hong Kong
- Employees
- 812
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Everest Medicines Ltd. Business Overview & Revenue Model
Company Description
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them...
Everest Medicines Ltd. Financial Statement Overview
Summary
Revenue growth is very strong (~95% in 2025 vs 2024) with healthy gross profitability (~60% gross margin), but the company remains loss-making (net margin ~-17%) and continues to burn cash with negative operating and free cash flow in 2025 despite improvement versus 2024.
Income Statement
46NeutralBalance Sheet
72PositiveCash Flow
34Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.41B | 1.71B | 706.68M | 125.93M | 12.79M | 54.00K |
| Gross Profit | 1.68B | 1.18B | 528.89M | 91.52M | 8.15M | 31.00K |
| EBITDA | 64.54M | -187.37M | -646.59M | -744.63M | -198.91M | -972.78M |
| Net Income | -53.92M | -297.77M | -1.04B | -844.46M | -247.28M | -1.01B |
Balance Sheet | ||||||
| Total Assets | 8.45B | 6.84B | 4.96B | 5.77B | 6.61B | 6.65B |
| Cash, Cash Equivalents and Short-Term Investments | 2.04B | 2.73B | 1.60B | 2.35B | 1.65B | 2.64B |
| Total Debt | 1.99B | 925.98M | 575.61M | 510.63M | 534.64M | 485.03M |
| Total Liabilities | 3.22B | 1.53B | 886.05M | 804.10M | 960.25M | 753.83M |
| Stockholders Equity | 5.23B | 5.31B | 4.07B | 4.97B | 5.65B | 5.89B |
Cash Flow | ||||||
| Free Cash Flow | -281.69M | -172.32M | -744.92M | -1.04B | -1.59B | -1.71B |
| Operating Cash Flow | -183.59M | -109.96M | -679.51M | -769.19M | -1.16B | -729.94M |
| Investing Cash Flow | -2.19B | -674.78M | 974.40M | 752.50M | -1.03B | -975.82M |
| Financing Cash Flow | 2.64B | 1.75B | 37.80M | 10.10M | -25.31M | -76.51M |
Everest Medicines Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1952, the sentiment is Negative. The current price of 27.02 is below the 20-day moving average (MA) of 30.54, below the 50-day MA of 30.56, and below the 200-day MA of 32.40, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 41.94 is Neutral, neither overbought nor oversold. The STOCH value of 10.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1952.
Everest Medicines Ltd. Peers Comparison
Overall Rating
HK:996965Neutral- HK:195257Neutral
HK:261646.6Neutral
HK:968846Neutral
HK:699645Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:9969 | 65Neutral | HKD 16.81B | 12.42 | 17.47% | ― | 146.27% | ― |
| HK:1952 | 57Neutral | HKD 9.58B | -145.11 | -1.02% | ― | 192.64% | 92.31% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2616 | 47Neutral | HKD 7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
| HK:9688 | 46Neutral | HKD 21.69B | -12.70 | -27.40% | ― | 5.38% | 16.86% |
| HK:6996 | 45Neutral | HKD 1.80B | 29.59 | 6.51% | ― | 605.95% | ― |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1952 | Everest Medicines Ltd. | 27.02 | -22.34 | -45.26% | |
| HK:9688 | Zai Lab Ltd | 17.37 | -3.65 | -17.36% | |
| HK:6996 | Antengene Corporation Limited | 2.79 | -2.33 | -45.51% | |
| HK:9969 | InnoCare Pharma Ltd. | 11.25 | -3.37 | -23.05% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2616 | CStone Pharmaceuticals | 4.94 | -1.28 | -20.58% |
Everest Medicines Ltd. Corporate Events
Everest Medicines Sets Virtual EGM to Approve Strategic Pharma Cooperation
Everest Medicines has called an extraordinary general meeting for 16 November 2026, to be held virtually via an online platform, allowing shareholders to attend, vote and submit questions remotely without physical presence. The meeting will seek shar...
Everest Medicines Sets Record Date and Book Closure for November Extraordinary Meeting
Everest Medicines Limited has scheduled an extraordinary general meeting for 16 November 2026, setting the same day as the record date to determine shareholders’ eligibility to attend and vote. The company has outlined specific arrangements for...
Everest Medicines Sets Up ESG Committee to Strengthen Governance
Everest Medicines has established an Environmental, Social and Governance Committee to oversee ESG matters across the group, including climate-related risks and opportunities. The committee will guide the development and implementation of ESG strateg...
Everest Medicines Sets Up ESG Committee to Strengthen Governance
Everest Medicines has established an Environmental, Social and Governance Committee effective 28 September 2026, underscoring a more formalized approach to sustainability and stakeholder oversight. The committee will comprise at least three members,...
Everest Medicines Updates Board Composition and Governance Structure
Everest Medicines Limited has outlined the composition of its board of directors, naming Yifang Wu as chairman, Yongqing Luo as chief executive officer and Ian Ying Woo as president and chief financial officer. The board also includes non-executive a...
Everest Medicines Strikes Strategic Cooperation Deal With Hasten for China Distribution
Everest Medicines has signed a Strategic Cooperation Framework Agreement with Hasten to establish a comprehensive framework for supply, distribution, manufacturing and commercialization of pharmaceutical products in mainland China. The deal is design...
Everest Medicines Wins China Approval for First Self-Administered PSVT Nasal Spray
Everest Medicines has secured approval from China’s National Medical Products Administration for CARDAMYST (etripamil), a self-administered nasal spray to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rh...
Everest Medicines Publishes Unaudited Interim Results for First Half of 2026
Everest Medicines Limited has released its unaudited interim results for the six months ended 30 June 2026, in line with Hong Kong Stock Exchange listing requirements. The interim report, reviewed by the audit committee and Ernst & Young, is avai...
Everest Medicines Sets Out Board Structure and Key Governance Committees
Everest Medicines Limited, a Cayman Islands-incorporated and Hong Kong-listed biopharmaceutical company, develops and commercializes innovative therapies and is overseen by a board that includes executive leadership for operations and finance alongsi...
Everest Medicines Reshapes Board With Director Resignation and New Appointment
Everest Medicines announced that non-executive director William Ki Chul Cho will resign effective 14 August 2026 to focus on other business interests, with no disagreements reported with the board or issues requiring shareholder attention. The board...
Everest Medicines Sets Board Meeting to Approve 2026 Interim Results
Everest Medicines Limited has scheduled a board meeting for 18 August 2026 to review and approve the group’s interim financial results for the six months ended 30 June 2026. The meeting will also address other corporate matters, signaling routi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026